Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection

Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):399-405. doi: 10.1161/01.ATV.0000152233.80082.9c. Epub 2004 Dec 2.

Abstract

Objective: Dyslipidemia is common among patients receiving antiretroviral therapy for HIV infection. The purpose of this study was to determine whether postprandial lipemia contributes to the dyslipidemia observed in HIV-positive patients taking antiretroviral therapy.

Methods and results: A standardized fat load was administered to 65 subjects (group 1 35 HIV-positive subjects receiving protease inhibitors [PIs]; group 2 20 HIV-positive subjects not receiving PIs; group 3 10 HIV-negative controls). Serum triglycerides, retinyl palmitate, and lipoproteins were measured using enzymatic and nuclear magnetic resonance spectroscopic techniques. Compared with HIV-negative controls, peak postprandial retinyl palmitate and large very low-density lipoprotein (VLDL) levels occurred later in both HIV-positive groups, and a delayed decrease in serum triglycerides was observed. However, postprandial areas under the curve (AUCs) for triglycerides, retinyl palmitate, chylomicrons, and large VLDL were similar. Postprandial AUCs for intermediate-density lipoproteins (IDLs) and low-density lipoproteins (LDLs) were higher in group 1 than groups 2 and 3 (all P<0.035).

Conclusions: Postprandial clearance of triglyceride-rich lipoproteins is delayed in HIV-positive individuals receiving antiretroviral therapy. Compared with HIV-positive individuals not on PIs, those taking PIs do not have increased postprandial triglyceride-rich lipoproteins but do have increased postprandial IDLs and LDLs. An oral fat load was administered to 55 HIV-positive and 10 HIV-negative individuals. Postprandial clearance of triglyceride-rich lipoproteins was delayed in HIV-positive individuals. Compared with HIV-positive subjects not on PIs, those taking PIs do not have increased postprandial triglyceride-rich lipoproteins but do have increased postprandial intermediate-density and low-density lipoproteins.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active* / adverse effects
  • Apolipoproteins E / blood
  • Apolipoproteins E / genetics
  • Area Under Curve
  • Blood Glucose / analysis
  • Chylomicrons / blood
  • Coronary Disease / epidemiology
  • Dietary Fats / administration & dosage*
  • Diterpenes
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / pharmacology
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / chemically induced*
  • Hypertension / epidemiology
  • Insulin / blood
  • Lipoproteins / blood*
  • Lipoproteins, IDL
  • Lipoproteins, LDL / blood
  • Lipoproteins, VLDL / blood
  • Male
  • Postprandial Period*
  • Retinyl Esters
  • Risk Factors
  • Smoking / epidemiology
  • Triglycerides / blood
  • Vitamin A / analogs & derivatives*
  • Vitamin A / blood

Substances

  • Anti-HIV Agents
  • Apolipoproteins E
  • Blood Glucose
  • Chylomicrons
  • Dietary Fats
  • Diterpenes
  • HIV Protease Inhibitors
  • Insulin
  • Lipoproteins
  • Lipoproteins, IDL
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Retinyl Esters
  • Triglycerides
  • Vitamin A
  • retinol palmitate